{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-006599","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.152747+00:00","generated_at":"2026-05-28T01:19:30.437349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ","bullets":["Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.","Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.","CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.","Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.","Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-006599","json":"https://secwatch.observer/filing/0001193125-25-006599.json","markdown":"https://secwatch.observer/filing/0001193125-25-006599.md","text":"https://secwatch.observer/filing/0001193125-25-006599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/0001193125-25-006599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/d914343d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:19:30.437349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}